Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (USD $)	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Statements Of Operations and Comprehensive Income (Loss) [Abstract]
Net sales	$ 4,659,454	$ 4,540,442
Costs of sales	(2,993,828)	(2,953,211)
Gross profit	1,665,626	1,587,231
Selling expenses	(659,614)	(546,053)
Administrative expenses	(981,590)	(541,004)
Depreciation and amortization	(64,315)	(11,666)
Income from operations	(39,893)	488,508
Other income/expense	3,268
Interest income	7,333	21,201
Interest expense	(215,059)	(373,087)
Amortization of discount on notes	(402,394)	(690,903)
Loss before income taxes	(646,745)	(554,281)
Income tax expense	(32,099)	(116,696)
Net loss	(678,844)	(670,977)
Net loss attributable to non-controlling interest	(2,515)
Net loss attributable to Tanke Biosciences Corporation	(676,329)	(670,977)
Net loss	(678,844)	(670,977)
Other comprehensive income, net of tax:
Foreign currency translation adjustments	131,970	112,486
Comprehensive loss	(546,874)	(558,491)
Comprehensive loss attributable to non-controlling interest	(1,572)
Comprehensive loss attributable to Tanke Biosciences Corporation	$ (545,302)	$ (558,491)
Loss per common share:
Basic and diluted	$ (0.05)	$ (0.05)
Weighted average number of common shares used in computation
Basic and diluted	13,324,083	13,324,083